This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
ESMO 2022
Presentations
Tucatinib | Colorectal Cancer | 361P
Tucatinib Plus Trastuzumab in Patients (Pts) with HER2-positive Metastatic Colorectal Cancer (mCRC): Patient-Reported Outcomes (PROs) From Phase 2 Study MOUNTAINEER
Tucatinib | Colorectal Cancer | 438TIP
MOUNTAINEER-03: Phase 3 Study of Tucatinib, Trastuzumab, and mFOLFOX6 as Firstline Treatment in HER2+ Metastatic Colorectal Cancer (Trial in Progress)
Tucatinib | Colorectal Cancer | 376P
Impact of anti-EGFR Therapies on HER2-positive Metastatic Colorectal Cancer (HER2+ mCRC): A Systematic Literature Review and Meta-analysis of Clinical Outcomes
Enfortumab Vedotin | Urothelial Cancer | LBA73
Study EV-103 Cohort K: Antitumor Activity of Enfortumab Vedotin (EV) Monotherapy or in Combination with Pembrolizumab (P) in Previously Untreated Cisplatin-ineligible Patients (pts) with Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
Tucatinib | Colorectal Cancer | LBA27
Additional Analyses of MOUNTAINEER: A Phase 2 Study of Tucatinib and Trastuzumab for HER2-positive mCRC
Disitamab Vedotin | Urothelial Carcinoma | 1779TIP
Phase 2 Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin in Patients (pts) With HER2-Expressing Urothelial Carcinoma (RC48G001, Trial in Progress)